The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries

Episode 3: Maintenance and Reliever Therapy in Moderate to Severe Asthma

Host: Gerald B. Lee, MD, FACAAI

Experts: Leonard B. Bacharier, MD, FACAAI, Alan P. Baptist, MD, MPH, FACAAI

Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: MART therapy, ICS/formoterol, FDA guidelines, pediatric application.

Learning Objectives:

• Expose the prevalence of asthma and exacerbations in the US

Speaker Disclosures:

Gerald B. Lee, MD, FACAAI

No relevant financial relationships with ineligible companies to disclose

Leonard B. Bacharier, MD, FACAAI

Advisor: DBV Technologies

Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi

Researcher: AstraZeneca, Sanofi

Speaker: Regeneron, Sanofi

Alan P. Baptist, MD, MPH, FACAAI

Advisor: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi

Researcher: AstraZeneca, Novartis, Regeneron

This podcast miniseries is supported by a grant from AstraZeneca.